{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:41:51Z","timestamp":1794649311129,"version":"4.9.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.cpcardiol.2021.101035","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T13:08:38Z","timestamp":1635426518000},"page":"101035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events \u2013 A Review on Vorapaxar"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2511-2119","authenticated-orcid":false,"given":"Rahul","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muling","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anila","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya K.","family":"Aedma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purva","family":"Ranchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva V.","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Kluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Combs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nainesh C.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2021.101035_bib0001","first-page":"1","article-title":"Prevalence of uncontrolled risk factors for cardiovascular disease: United States, 1999-2010","author":"Fryar","year":"2012","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0002","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0003","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa067193","article-title":"Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents","volume":"356","author":"Stone","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0004","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCINTERVENTIONS.111.967083","article-title":"Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials","volume":"5","author":"Palmerini","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0005","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1160\/TH09-03-0192","article-title":"Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis","volume":"102","author":"Jennings","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0006","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/35025229","article-title":"Thrombin signalling and protease-activated receptors","volume":"407","author":"Coughlin","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0007","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40268-016-0158-4","article-title":"Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease","volume":"17","author":"Gryka","year":"2017","journal-title":"Drugs R D"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0008","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2165\/11538060-000000000-00000","article-title":"Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555","volume":"70","author":"Leonardi","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0009","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0010","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpdd.38","article-title":"The Absence of a Clinically Significant Effect of Food on the Single Dose Pharmacokinetics of Vorapaxar, a PAR-1 Antagonist, in Healthy Adult Subjects","volume":"2","author":"Behm","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0011","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/cpdd.30","article-title":"Effect of Food, Antacid, and Age on the Pharmacokinetics of the Oral Thrombin Receptor Antagonist Vorapaxar (SCH 530348) in Healthy Volunteers","volume":"2","author":"Kosoglou","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0012","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1124\/dmd.110.035493","article-title":"Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist","volume":"39","author":"Ghosal","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0013","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00228-011-1120-6","article-title":"Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects","volume":"68","author":"Kosoglou","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0014","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/cpdd.49","article-title":"Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT\/QTc interval in healthy volunteers: A randomized, placebo- and positive-controlled, parallel group trial","volume":"3","author":"Kosoglou","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0015","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4103\/0975-7406.171690","article-title":"Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction","volume":"8","author":"Kehinde","year":"2016","journal-title":"J Pharm Bioallied Sci"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0016","article-title":"Improving Outcomes in Cardiovascular Diseases: A Review on Vorapaxar","author":"Chaudhary","year":"2021","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0017","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/cpdd.354","article-title":"Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy Volunteers","volume":"7","author":"Anderson","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0018","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jacbts.2019.07.011","article-title":"Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study","volume":"4","author":"Franchi","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0019","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","article-title":"Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0020","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ahj.2014.06.017","article-title":"Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)","volume":"168","author":"Jones","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0021","first-page":"e726","article-title":"2016 AHA\/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0022","series-title":"Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) (XLPADTRACE)","year":"2016"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0023","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.114.013774","article-title":"Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial","volume":"131","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0024","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jacc.2013.10.048","article-title":"Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)","volume":"63","author":"Whellan","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0025","first-page":"164","article-title":"Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2 degrees P-TIMI 50 trial","volume":"6","author":"Kosova","year":"2017","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0026","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.amjcard.2015.12.051","article-title":"Role of Vorapaxar After Coronary Revascularization","volume":"117","author":"Sharma","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0027","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1586\/14737175.2015.1111761","article-title":"Vorapaxar for secondary stroke prevention: perspectives and obstacles","volume":"15","author":"Serebruany","year":"2015","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0028","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0140-6736(12)61269-0","article-title":"Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial","volume":"380","author":"Scirica","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0029","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.015865","article-title":"Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study","volume":"9","author":"Franchi","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0031","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2352-3018(18)30214-5","article-title":"Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial","volume":"5","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0032","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1055\/s-0038-1655767","article-title":"Inhibition of Protease-Activated Receptor (PAR1) Reduces Activation of the Endothelium, Coagulation, Fibrinolysis and Inflammation during Human Endotoxemia","volume":"118","author":"Schoergenhofer","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0033","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/1129729819887269","article-title":"A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation","volume":"21","author":"Olivier","year":"2020","journal-title":"J Vasc Access"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0034","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00228-012-1217-6","article-title":"Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease","volume":"68","author":"Kosoglou","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0035","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-015-0387-9","article-title":"Vorapaxar: a review of its use in the long-term secondary prevention of atherothrombotic events","volume":"75","author":"Frampton","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0036","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1097\/MJT.0000000000000395","article-title":"Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association?","volume":"24","author":"Serebruany","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0037","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ijcard.2015.08.177","article-title":"The FDA report on vorapaxar in the elderly: A convoluted dilemma","volume":"201","author":"Serebruany","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0038","unstructured":"ClinicalTrials.gov. Vorapaxar and Lower Extremity Bypass Grafts. November 29, 2016; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02975583."},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0039","unstructured":"ClinicalTrials.gov. Trial to Assess the Ocular Safety of Vorapaxar in Participants With Atherosclerosis 2014; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00617123."},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0040","unstructured":"ClinicalTrials.gov. Influence of Vorapaxar on Thrombin Generation and Coagulability. 2017; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03207451."},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0041","unstructured":"ClinicalTrials.gov. Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction. 2014; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00684515."},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0042","unstructured":"ClinicalTrials.gov. Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome. 2014; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00684203."},{"key":"10.1016\/j.cpcardiol.2021.101035_bib0043","unstructured":"ClinicalTrials.gov. A Bioequivalence Study of SCH 530348 2.5 mg Tablets. 2011; Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01358344."},{"issue":"9667","key":"10.1016\/j.cpcardiol.2021.101035_bib0044","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(09)60230-0","article-title":"Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study","volume":"373","author":"Becker","year":"2009","journal-title":"Lancet"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280621002425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280621002425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:08:32Z","timestamp":1758938912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280621002425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0146280621002425"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2021.101035","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events \u2013 A Review on Vorapaxar","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2021.101035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101035"}}